Rigel Pharmaceuticals, Inc.
ACVR2A-specific antibody and method of treatment of muscle atrophy

Abstract:

The present disclosure provides antibodies that specifically bind to and block signaling by ACVR2A, i.e., ACVR2A but not ACVR2B, as well as methods for using the same. The antibodies may be used for the treatment of a number of conditions associated with muscle atrophy, as well as other conditions.